专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07572791B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US07572791B2
公开(公告)日：2009-08-11
申请号：US12019061
申请日：2008-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5375 , C07D413/02
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

2. 发明申请

US20080206312A1 Therapeutic Morpholino-Substituted Compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US20080206312A1
公开(公告)日：2008-08-28
申请号：US12019061
申请日：2008-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , C07D413/04 , A61K9/12 , A61K47/06 , A61P9/00 , A61P11/00 , A61P35/04 , A61P7/00
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

3. 发明申请

US20080312233A1 Therapeutic Morpholino-Substituted Compounds 审中-公开
公开(公告)号：US20080312233A1
公开(公告)日：2008-12-18
申请号：US12115563
申请日：2008-05-06
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , A61P11/00 , A61P9/00
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

4. 发明授权

US07405211B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US07405211B2
公开(公告)日：2008-07-29
申请号：US10961062
申请日：2004-10-12
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K31/5377 , C07D413/04
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

5. 发明申请

US20050085471A1 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US20050085471A1
公开(公告)日：2005-04-21
申请号：US10961062
申请日：2004-10-12
申请人： Alan Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
发明人： Alan Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yaip , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K9/02 , A61K9/08 , A61K9/12 , A61K9/20 , A61K9/48 , A61K31/5377 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04 , C07D413/04
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

6. 发明授权

US06977255B2 Therapeutic morpholino-substituted compounds 失效
标题翻译：治疗性吗啉取代的化合物
公开(公告)号：US06977255B2
公开(公告)日：2005-12-20
申请号：US10181485
申请日：2001-01-24
申请人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yap , Hishani Parbaharan , Phil Thompson
发明人： Alan D. Robertson , Shaun Jackson , Vijaya Kenche , Cindy Yap , Hishani Parbaharan , Phil Thompson
IPC分类号： A61K9/02 , A61K9/08 , A61K9/12 , A61K9/20 , A61K9/48 , A61K31/5377 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04 , A61K31/352
CPC分类号： C07D215/38 , C07D311/22 , C07D311/58 , C07D311/64 , C07D471/04
摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
摘要翻译：吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 包括诸如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌等癌症的肿瘤，以及与无序白细胞功能相关的疾病，例如自身免疫性和炎性疾病。

7. 发明申请

US20080310408A1 Internet Protocol Television 审中-公开
标题翻译：互联网协议电视
公开(公告)号：US20080310408A1
公开(公告)日：2008-12-18
申请号：US11828962
申请日：2007-07-26
申请人： Phil Thompson , J. Connon Samuel , Jacqueline A. Totten , Mary K. Whelan
发明人： Phil Thompson , J. Connon Samuel , Jacqueline A. Totten , Mary K. Whelan
IPC分类号： H04Q11/00
CPC分类号： H04L65/4076 , G06Q30/02 , H04L12/185 , H04L67/22 , H04L67/34 , H04N7/17318 , H04N21/2143 , H04N21/2181 , H04N21/252 , H04N21/2543 , H04N21/26258 , H04N21/4825 , H04N21/4826 , H04N21/6125 , H04N21/64322 , H04N21/812 , H04N21/8133
摘要： Distributing data includes establishing an asset classification for an asset or group of assets and assigning at least one of the asset classifications to a network device and another asset classification to a first set of data. The first set of data is transmitted over a network that includes the network device and is received in the network device on the condition that the asset classification assigned to the first set of data is the same as the asset classification assigned to the network device.
摘要翻译：分配数据包括为资产或资产组建立资产分类，并将至少一种资产分类分配给网络设备，将另一种资产分类分配给第一组数据。第一组数据通过包括网络设备的网络传输，并且在分配给第一组数据的资产分类与分配给网络设备的资产分类相同的条件下被接收在网络设备中。

8. 发明申请

US20070034161A1 Animal feeding bowl 审中-公开
标题翻译：动物饲养碗
公开(公告)号：US20070034161A1
公开(公告)日：2007-02-15
申请号：US11318178
申请日：2005-12-23
申请人： Phil Thompson
发明人： Phil Thompson
IPC分类号： A01K5/01
CPC分类号： A01K5/0135 , A01K5/0114
摘要： The present invention relates to packaging and in particular to packaging for pet food that may also be used as an animal feeding bowl. Known containers are relatively lightweight and in consuming food from them a pet may push the bowl around during feeding resulting in inadvertent spillage of the pet food from the container. This results not only in waste of the pet food, but creates mess requiring cleaning. Packaging which may also be used as an animal feeding bowl is disclosed comprising a central bowl and a releasable lid, in which a base of the central bowl is provided with a plurality of anti-slip means formed from a hot melt adhesive. It is an advantage that such packaging is simple to manufacture and does not create additional waste requiring cleaning by, for example, a person responsible for feeding the pet.
摘要翻译：本发明涉及包装，特别是宠物食品的包装，也可用作动物饲料碗。已知的容器相对较轻，并且在食用食物时，宠物可以在进料期间推动碗，从而导致宠物食物从容器中的不经意的溢出。这不仅造成宠物食物的浪费，而且会造成需要清洁的混乱。公开了还可以用作动物饲料碗的包装，其包括中央碗和可释放的盖，其中中央碗的基部设置有由热熔性粘合剂形成的多个防滑装置。这种包装容易制造并且不产生需要由例如负责喂养宠物的人进行清洁的额外废物是有利的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式